Comparative Pharmacology
Head-to-head clinical analysis: BENADRYL versus CLARITIN HIVES RELIEF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENADRYL versus CLARITIN HIVES RELIEF.
BENADRYL vs CLARITIN HIVES RELIEF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antihistamine; inverse agonist at histamine H1 receptors, blocking histamine-induced vasodilation, increased capillary permeability, and bronchoconstriction; also anticholinergic and sedative.
Selective inverse agonist at histamine H1 receptors, blocking histamine-mediated effects in allergic reactions.
25-50 mg orally every 4-6 hours as needed; maximum 300 mg per day. Alternatively, 10-50 mg intramuscularly or intravenously once, maximum 100 mg per dose (IV route preferred).
10 mg orally once daily
None Documented
None Documented
Terminal elimination half-life 4-8 hours; prolonged in hepatic impairment (up to 20 hours).
8.4 hours (range 3-20 hours) for loratadine; 28 hours (range 8.8-92 hours) for active metabolite desloratadine, allowing once-daily dosing.
Renal (90% as metabolites, <5% unchanged); minimal biliary/fecal.
Renal: ~40% as metabolites, <1% unchanged; Fecal: ~40%; Biliary: minor contribution.
Category C
Category C
Antihistamine
Antihistamine